EU medical technology industry: mid-2007 round-up of regulatory developments
This article was originally published in Clinica
Executive Summary
For those returning from spending a few summer weeks at the beach or in other vacation pursuits, recent developments in the medtech industry may seem rather a blur. Much regulatory progress critical to the future of the medtech industry was made during the first half of 2007. Here, Amanda Maxwell summarises the main points in a whistle-stop tour
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.